AGM-331

AGM-331 is a preclinical peptide-based therapeutic candidate developed by Anygen, a South Korean biotechnology company specializing in peptide drug development. It is categorized as a targeted anti-cancer therapy, utilizing Anygen's proprietary cancer-targeting peptide (CTP) technology. The molecule is designed to selectively recognize and bind to specific markers or receptors overexpressed on the surface of cancer cells, thereby delivering a therapeutic effect directly to the tumor site while sparing healthy tissues. AGM-331 is currently undergoing preclinical evaluation to determine its safety and efficacy profile for the treatment of various solid tumors.